查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1386124

伊波拉出血热治疗药物和疫苗市场报告：2030 年趋势、预测和竞争分析

Ebola Drug and Vaccine Market Report: Trends, Forecast and Competitive Analysis to 2030
出版日期: | 出版商: Lucintel | 英文 150 Pages | 商品交期: 3个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

简介目录

伊波拉出血热治疗药物和疫苗的趋势和预测

至2030年，全球伊波拉出血热治疗和疫苗市场预计将达到1.687亿美元，2024年至2030年的年复合成长率为28.6%。该市场的主要驱动因素是感染疾病流行的日益严重以及政府在伊波拉出血热研究和伊波拉出血热治疗和疫苗开发方面的积极配合措施。全球伊波拉出血热治疗和疫苗市场前景看好，医院和诊所市场以及门诊手术中心市场都有机会。

伊波拉出血热治疗和疫苗市场洞察

Lucintel 预测扎伊尔将在预测期内实现最高的成长。

由于通用感染疾病日益流行、先进医疗技术的采用增多以及医疗基础设施发达，北美将继续成为最大的地区。

本报告回答了 11 个关键问题：

  • Q.1. 细分市场中最有前途和高成长的机会是什么？
  • Q.2.哪个细分市场将以更快的速度成长？为什么？
  • Q.3.您认为哪些地区未来会出现更快的成长？为什么？
  • Q.4. 影响市场动态的主要因素有哪些？市场的主要挑战和商业风险是什么？
  • Q.5. 这个市场的商业风险和竞争威胁是什么？
  • Q.6.这个市场有哪些新趋势？为什么？
  • Q.7.市场客户需求有何改变？
  • Q.8. 该市场有哪些新发展以及哪些公司处于领先地位？
  • Q.9.这个市场的主要企业有哪些？主要企业采取哪些策略配合措施来发展业务？
  • Q.10. 该市场上的竞争产品有哪些？由于材料或产品替代而导致市场占有率下降的威胁有多大？
  • Q.11.过去年度发生了哪些併购事件，对产业产生了哪些影响？

目录

第1章执行摘要

第2章全球伊波拉出血热治疗药物与疫苗市场：市场动态

  • 简介、背景、分类
  • 供应链
  • 产业驱动因素与挑战

第3章2018-2030年市场趋势及预测分析

  • 宏观经济趋势（2018-2023）与预测（2024-2030）
  • 全球伊波拉出血热治疗药物和疫苗市场趋势（2018-2023）和预测（2024-2030）
  • 依新药类型划分：全球伊波拉出血热治疗与疫苗市场
    • Z图
    • 法匹拉韦
    • GS-5734
    • Tkm-伊波拉出血热
    • AVI-7537
  • 依疫苗类型：全球伊波拉出血热疗法和疫苗市场
    • Cad3-Zebov
    • 鲁布·泽博夫
    • 其他的
  • 按菌株类型：全球伊波拉出血热疗法和疫苗市场
    • 札伊尔
    • 苏丹
    • 泰国森林
    • 休息
    • 本迪布焦病毒
  • 按最终用途划分：全球伊波拉出血热治疗药物和疫苗市场
    • 医院和诊所
    • 门诊手术中心
    • 其他的

第4章2018-2030年分地区市场趋势及预测分析

  • 全球伊波拉出血热治疗药物和疫苗市场（按地区）
  • 北美伊波拉出血热治疗与疫苗市场
  • 欧洲伊波拉出血热治疗与疫苗市场
  • 亚太伊波拉出血热治疗药物与疫苗市场
  • 其他区域伊波拉出血热治疗药物/疫苗市场

第5章竞争分析

  • 产品系列分析
  • 营运整合
  • 波特五力分析

第6章成长机会与策略分析

  • 成长机会分析
    • 按新药类型分類的全球伊波拉出血热治疗和疫苗市场成长机会
    • 全球伊波拉出血热热药物和疫苗市场成长机会（以疫苗类型）
    • 按菌株类型分類的全球伊波拉出血热治疗和疫苗市场的成长机会
    • 全球伊波拉出血热治疗和疫苗市场成长机会（按最终用途）
    • 全球伊波拉出血热治疗和疫苗市场成长机会（按地区）
  • 全球伊波拉出血热治疗与疫苗市场新趋势
  • 战略分析
    • 新产品开发
    • 扩大全球伊波拉出血热治疗和疫苗市场的产能
    • 全球伊波拉出血热治疗和疫苗市场的合併、收购和合资企业
    • 认证和许可

第7章主要企业概况

  • Arbutus Biopharma
  • GlaxoSmithKline
  • Johnson & Johnson Services
  • Hemispherx Biopharma
  • BioCryst Pharmaceuticals
  • NanoViricides
  • NewLink Genetics
简介目录

Ebola Drug and Vaccine Trends and Forecast

The future of the global ebola drug and vaccine market looks promising with opportunities in the hospital & clinic and ambulatory surgical center markets. The global ebola drug and vaccine market is expected to reach an estimated $168.7 million by 2030 with a CAGR of 28.6% from 2024 to 2030. The major drivers for this market are growing prevalence of infectious diseases and supportive government initiatives towards ebola research and development of ebola drugs and vaccines.

A more than 150-page report is developed to help in your business decisions.

Ebola Drug and Vaccine by Segment

The study includes a forecast for the global ebola drug and vaccine by novel drug type, vaccine type, strain type, end use, and region.

Ebola Drug and Vaccine Market by Novel Drug Type [Shipment Analysis by Value from 2018 to 2030]:

  • Zmapp
  • Favipiravir
  • Gs-5734
  • Tkm-Ebola
  • Avi-7537

Ebola Drug and Vaccine Market by Vaccine Type [Shipment Analysis by Value from 2018 to 2030]:

  • Cad3-Zebov
  • Rvsv-Zebov
  • Others

Ebola Drug and Vaccine Market by Strain Type [Shipment Analysis by Value from 2018 to 2030]:

  • Zaire
  • Sudan
  • Tai Forest
  • Reston
  • Bundibugyo Virus

Ebola Drug and Vaccine Market by End Use [Shipment Analysis by Value from 2018 to 2030]:

  • Hospitals & Clinics
  • Ambulatory Surgical Centers
  • Others

Ebola Drug and Vaccine Market by Region [Shipment Analysis by Value from 2018 to 2030]:

  • North America
  • Europe
  • Asia Pacific
  • The Rest of the World

List of Ebola Drug and Vaccine Companies

Companies in the market compete on the basis of product quality offered. Major players in this market focus on expanding their manufacturing facilities, R&D investments, infrastructural development, and leverage integration opportunities across the value chain. With these strategies ebola drug and vaccine companies cater increasing demand, ensure competitive effectiveness, develop innovative products & technologies, reduce production costs, and expand their customer base. Some of the ebola drug and vaccine companies profiled in this report include-

  • Arbutus Biopharma
  • GlaxoSmithKline
  • Johnson & Johnson Services
  • Hemispherx Biopharma
  • BioCryst Pharmaceuticals
  • NanoViricides
  • NewLink Genetics

Ebola Drug and Vaccine Market Insights

Lucintel forecasts that zaire is expected to witness highest growth over the forecast period.

North America will remain the largest regiondue to growing prevalence of zoonotic diseases, rising adoption of advanced medical technologies, and presence of well-established healthcare infrastructure in the region.

Features of the Global Ebola Drug and Vaccine Market

Market Size Estimates: Ebola drug and vaccine market size estimation in terms of value ($M).

Trend and Forecast Analysis: Market trends (2018 to 2023) and forecast (2024 to 2030) by various segments and regions.

Segmentation Analysis: Ebola drug and vaccine market size by various segments, such as by novel drug type, vaccine type, strain type, end use, and region in terms of ($M).

Regional Analysis: Ebola drug and vaccine market breakdown by North America, Europe, Asia Pacific, and Rest of the World.

Growth Opportunities: Analysis of growth opportunities in different novel drug types, vaccine types, strain types, end uses, and regions for the ebola drug and vaccine market.

Strategic Analysis: This includes M&A, new product development, and competitive landscape of the ebola drug and vaccine market.

Analysis of competitive intensity of the industry based on Porter's Five Forces model.

FAQ

Q.1 What is the ebola drug and vaccine market size?

Answer: The global ebola drug and vaccine market is expected to reach an estimated $168.7 million by 2030.

Q.2 What is the growth forecast for ebola drug and vaccine market?

Answer: The global ebola drug and vaccine market is expected to grow with a CAGR of 28.6% from 2024 to 2030.

Q.3 What are the major drivers influencing the growth of the ebola drug and vaccine market?

Answer: The major drivers for this market are growing prevalence of infectious diseases and supportive government initiatives towards ebola research and development of ebola drugs and vaccines.

Q4. What are the major segments for ebola drug and vaccine market?

Answer: The future of the ebola drug and vaccine market looks promising with opportunities in the hospital & clinic and ambulatory surgical center markets.

Q5. Who are the key ebola drug and vaccine market companies?

Answer: Some of the key ebola drug and vaccine companies are as follows:

  • Arbutus Biopharma
  • GlaxoSmithKline
  • Johnson & Johnson Services
  • Hemispherx Biopharma
  • BioCryst Pharmaceuticals
  • NanoViricides
  • NewLink Genetics

Q6. Which ebola drug and vaccine market segment will be the largest in future?

Answer: Lucintel forecasts that zaire is expected to witness highest growth over the forecast period.

Q7. In ebola drug and vaccine market, which region is expected to be the largest in next 5 years?

Answer: North America will remain the largest regiondue to growing prevalence of zoonotic diseases, rising adoption of advanced medical technologies, and presence of well-established healthcare infrastructure in the region.

Q.8 Do we receive customization in this report?

Answer: Yes, Lucintel provides 10% customization without any additional cost.

This report answers following 11 key questions:

  • Q.1. What are some of the most promising, high-growth opportunities for the ebola drug and vaccine market by novel drug type (zmapp, favipiravir, gs-5734, tkm-ebola, and avi-7537), vaccine type (cad3-zebov, rvsv-zebov, and others), strain type (zaire, sudan, tai forest, reston, and bundibugyo virus), end use (hospitals & clinics, ambulatory surgical centers, and others), and region (North America, Europe, Asia Pacific, and the Rest of the World)?
  • Q.2. Which segments will grow at a faster pace and why?
  • Q.3. Which region will grow at a faster pace and why?
  • Q.4. What are the key factors affecting market dynamics? What are the key challenges and business risks in this market?
  • Q.5. What are the business risks and competitive threats in this market?
  • Q.6. What are the emerging trends in this market and the reasons behind them?
  • Q.7. What are some of the changing demands of customers in the market?
  • Q.8. What are the new developments in the market? Which companies are leading these developments?
  • Q.9. Who are the major players in this market? What strategic initiatives are key players pursuing for business growth?
  • Q.10. What are some of the competing products in this market and how big of a threat do they pose for loss of market share by material or product substitution?
  • Q.11. What M&A activity has occurred in the last 5 years and what has its impact been on the industry?

Table of Contents

1. Executive Summary

2. Global Ebola Drug and Vaccine Market : Market Dynamics

  • 2.1: Introduction, Background, and Classifications
  • 2.2: Supply Chain
  • 2.3: Industry Drivers and Challenges

3. Market Trends and Forecast Analysis from 2018 to 2030

  • 3.1. Macroeconomic Trends (2018-2023) and Forecast (2024-2030)
  • 3.2. Global Ebola Drug and Vaccine Market Trends (2018-2023) and Forecast (2024-2030)
  • 3.3: Global Ebola Drug and Vaccine Market by Novel Drug Type
    • 3.3.1: Zmapp
    • 3.3.2: Favipiravir
    • 3.3.3: Gs-5734
    • 3.3.4: Tkm-Ebola
    • 3.3.5: Avi-7537
  • 3.4: Global Ebola Drug and Vaccine Market by Vaccine Type
    • 3.4.1: Cad3-Zebov
    • 3.4.2: Rvsv-Zebov
    • 3.4.3: Others
  • 3.5: Global Ebola Drug and Vaccine Market by Strain Type
    • 3.5.1: Zaire
    • 3.5.2: Sudan
    • 3.5.3: Tai Forest
    • 3.5.4: Reston
    • 3.5.5: Bundibugyo Virus
  • 3.6: Global Ebola Drug and Vaccine Market by End Use
    • 3.6.1: Hospitals & Clinics
    • 3.6.2: Ambulatory Surgical Centers
    • 3.6.3: Others

4. Market Trends and Forecast Analysis by Region from 2018 to 2030

  • 4.1: Global Ebola Drug and Vaccine Market by Region
  • 4.2: North American Ebola Drug and Vaccine Market
    • 4.2.1: North American Ebola Drug and Vaccine Market by Strain Type: Zaire, Sudan, Tai Forest, Reston, and Bundibugyo Virus
    • 4.2.2: North American Ebola Drug and Vaccine Market by End Use: Hospitals & Clinics, Ambulatory Surgical Centers, and Others
  • 4.3: European Ebola Drug and Vaccine Market
    • 4.3.1: European Ebola Drug and Vaccine Market by Strain Type: Zaire, Sudan, Tai Forest, Reston, and Bundibugyo Virus
    • 4.3.2: European Ebola Drug and Vaccine Market by End Use: Hospitals & Clinics, Ambulatory Surgical Centers, and Others
  • 4.4: APAC Ebola Drug and Vaccine Market
    • 4.4.1: APAC Ebola Drug and Vaccine Market by Strain Type: Zaire, Sudan, Tai Forest, Reston, and Bundibugyo Virus
    • 4.4.2: APAC Ebola Drug and Vaccine Market by End Use: Hospitals & Clinics, Ambulatory Surgical Centers, and Others
  • 4.5: ROW Ebola Drug and Vaccine Market
    • 4.5.1: ROW Ebola Drug and Vaccine Market by Strain Type: Zaire, Sudan, Tai Forest, Reston, and Bundibugyo Virus
    • 4.5.2: ROW Ebola Drug and Vaccine Market by End Use: Hospitals & Clinics, Ambulatory Surgical Centers, and Others

5. Competitor Analysis

  • 5.1: Product Portfolio Analysis
  • 5.2: Operational Integration
  • 5.3: Porter's Five Forces Analysis

6. Growth Opportunities and Strategic Analysis

  • 6.1: Growth Opportunity Analysis
    • 6.1.1: Growth Opportunities for the Global Ebola Drug and Vaccine Market by Novel Drug Type
    • 6.1.2: Growth Opportunities for the Global Ebola Drug and Vaccine Market by Vaccine Type
    • 6.1.3: Growth Opportunities for the Global Ebola Drug and Vaccine Market by Strain Type
    • 6.1.4: Growth Opportunities for the Global Ebola Drug and Vaccine Market by End Use
    • 6.1.5: Growth Opportunities for the Global Ebola Drug and Vaccine Market by Region
  • 6.2: Emerging Trends in the Global Ebola Drug and Vaccine Market
  • 6.3: Strategic Analysis
    • 6.3.1: New Product Development
    • 6.3.2: Capacity Expansion of the Global Ebola Drug and Vaccine Market
    • 6.3.3: Mergers, Acquisitions, and Joint Ventures in the Global Ebola Drug and Vaccine Market
    • 6.3.4: Certification and Licensing

7. Company Profiles of Leading Players

  • 7.1: Arbutus Biopharma
  • 7.2: GlaxoSmithKline
  • 7.3: Johnson & Johnson Services
  • 7.4: Hemispherx Biopharma
  • 7.5: BioCryst Pharmaceuticals
  • 7.6: NanoViricides
  • 7.7: NewLink Genetics